|Previous Section||Index||Home Page|
Mr. Byrne: It is for primary care trusts to decide how to spend the funding allocations they are given in he light of local needs and priorities. Information on the amount spent on raising awareness of lupus is not held centrally.
The NHS Direct website contains specific information on lupus. The musculoskeletal framework, a best practice guide to supporting people with musculoskeletal conditions, will be published later this year. This will do much to raise awareness amongst health professionals and the general public for all musculoskeletal conditions, including lupus.
The main part of the Department's expenditure on health research is allocated to, and managed by,
8 Nov 2005 : Column 398W
national health service organisations. Details of individual projects supported in the NHS, including a significant number concerned with lupus, are to be found on the national research register at www.dh.gov.uk/research. The Medical Research Council, an independent body funded by the Department of Trade and Industry via the Office of Science and Technology, also funds medical research. It is not possible to identify the total amount spent on research into the treatment of lupus.
Ms Rosie Winterton: The vast majority of individuals with macular hole have their condition diagnosed by an optometrist during a routine sight test. Sight tests are free under the national health service to people aged 60 and over, children, individuals at particular risk of eye disease and those on a low income. Individuals who are identified as requiring further investigation can now be referred directly to hospital following an NHS funded sight test.
The Department has put a number of measures in place aimed at reducing waiting times in the NHS. By the end of 2005, no patient will have to wait more than 13 weeks for an out-patient appointment or more than six months for surgery, and most waits will be much shorter than this.
In many cases, surgery can stop the visual disturbances getting worse and can help sight to recover to a high standard. The final visual outcome, however, will depend on the size of the hole that has been treated. For those individuals whose sight is still affected after surgery, low vision aids may be of help. The NHS hospital eye service provides optical devices and loans low vision aids, such as high-powered reading lenses, hand-held and stand magnifiers and telescopes, to people with visual impairment. In addition, some primary care trusts have local arrangements for the provision of low vision aids through community based opticians.
Mr. Lansley: To ask the Secretary of State for Health how many finished episodes of care relating to the treatment of macular holes there have been in each year since 1997; and what the (a) mean and (b) median waiting time was in each year. 
Ms Rosie Winterton:
The following table shows the number of finished in-year admission episodes and the mean and median waiting times for those individuals whose primary diagnosis was degeneration of the macular and posterior pole.
8 Nov 2005 : Column 399W
|Finished in-year admission episodes||Mean waiting time in days||Median waiting time in days|
Ed Balls: To ask the Secretary of State for Health how much funding has been allocated to preventative and early intervention services for children's mental health disorders in (a) Normanton constituency, (b) Wakefield East primary care trust (PCT), (c) Wakefield West PCT, (d) Wakefield district and (e) West Yorkshire in 200506. 
Mr. Byrne: Funding is allocated directly to primary care trust (PCTs). It is for PCTs, in partnership with strategic health authorities and other local stakeholders, to determine how best to use their funds to meet national and local priorities for improving health, tackling health inequalities and modernising services.
|West Yorkshire PCTs||200506||200607||200708|
|Bradford South and West||158,353||192,836||210,881|
|Leeds North East||160,333||192,073||207,743|
|Leeds North West||172,126||208,941||228,463|
A team from University College London and the University of Newcastle upon Tyne have been chosen to lead a £20 million initiative to speed up the development of new medical treatments for dementia and neurodegenerative disease. The team will co-ordinate a network of national health service staff and resources across the country to expand the number and range of clinical trials of medical treatments for neurodegenerative diseases including motor neurone disease.
The network will offer unprecedented opportunities to bring the latest clinical treatments and trials to people in the United Kingdom. The new scheme will operate in close partnership with patient organisations to ensure that we are addressing the research questions that are of most importance to patients.
Jane Kennedy: I am satisfied that multiple sclerosis therapy centres should continue to be subject to the Healthcare Commission's regulatory regime. The Commission is developing costed options for regulating independent healthcare providers, including multiple sclerosis therapy centres. I expect these options to reflect the risk-based approach to inspection which the Commission has been developing. The Commission intends to consult on its proposals shortly.
Ms Rosie Winterton [holding answer 19 October 2005]: My right hon. Friend, the Secretary of State currently has no plans to visit Oxford, as her autumn schedule is now fixed. If my right hon. Friend would like to invite the Secretary of State for a visit then a formal request should be sent to the ministerial visits Unit room 448 Richmond House, 79 Whitehall, London SW1A 2NS, for consideration.
|Next Section||Index||Home Page|